<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02889237</url>
  </required_header>
  <id_info>
    <org_study_id>NL46035.072.13</org_study_id>
    <nct_id>NCT02889237</nct_id>
  </id_info>
  <brief_title>Fracture Healing Assessed by HR-pQCT After Administration of Calcium and Vitamin D</brief_title>
  <official_title>Assessment of Fracture Healing by High-resolution Peripheral Quantitative Computed Tomography (HR-pQCT) and Bone Strength Analysis in Standard Care and After Immediate Administration of Calcium and Vitamin D Supplementation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VieCuri Medical Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VieCuri Medical Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed as a single-blind RCT in 80 postmenopausal women to compare the effect&#xD;
      of immediate administration of daily calcium supplementation (1000 mg calcium) or two daily&#xD;
      dosages of calcium + vitamin D (1000 mg calcium + 880 IU vitamin D or 1000 mg calcium + 1760&#xD;
      IU vitamin D) to standard care (administration of vitamin D3 12 weeks after fracture) in&#xD;
      terms of calculated bone strength based on analysis of cortical and trabecular bone&#xD;
      parameters using HR-pQCT, fracture healing and functional outcome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone strength</measure>
    <time_frame>1 year</time_frame>
    <description>Bone strength parameters will be assessed by HRpQCT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fracture healing</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcome assessed by PRWE</measure>
    <time_frame>1 year</time_frame>
    <description>Functional outcome is assessed using Patient-Related Wrist Examination (PRWE) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcome assessed by QuickDASH</measure>
    <time_frame>1 year</time_frame>
    <description>Functional outcome is assessed using QuickDASH questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcome assessed using VAS for pain score</measure>
    <time_frame>1 year</time_frame>
    <description>Functional outcome is assessed using VAS for pain score on Visual Analogue Scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcome assessed using range of motion</measure>
    <time_frame>1 year</time_frame>
    <description>Functional outcome is assessed by measuremt of range of motion of the fractured wrist</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Bone Fracture</condition>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Start of calcium and vitamin D3 supplementation according to standard care, i.e. 12 weeks after fracture.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Immediate administration of daily calcium supplementation (1000 mg calcium)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcium and low dose vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Immediate administration of daily calcium + low dose vitamin D supplementation (1000 mg calcium + 880 IU vitamin D).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcium and high dose vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Immediate administration of daily calcium + high dose vitamin D supplementation (1000 mg calcium + 1760 IU vitamin D)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Already on treatment with Calcium or vitamin D</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients who are already treated with Calcium or Vitamin D.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Calcium</intervention_name>
    <description>Immediate administration of daily calcium supplementation for 12 weeks</description>
    <arm_group_label>Calcium</arm_group_label>
    <other_name>Cacit effervescent tablet '1000'</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Calcium + low dose vitamin D</intervention_name>
    <description>Immediate administration of daily calcium and low dose vitamin D (1 sachet CaD 1000/880) supplementation for 12 weeks</description>
    <arm_group_label>Calcium and low dose vitamin D</arm_group_label>
    <other_name>CaD® sachet 1000/880</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Calcium + high dose vitamin D</intervention_name>
    <description>Immediate administration of daily calcium and high dose vitamin D (2 sachets CaD 500/880) supplementation for 12 weeks</description>
    <arm_group_label>Calcium and high dose vitamin D</arm_group_label>
    <other_name>CaD® sachets 500/880</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Postmenopausal women older than 50 years who present themselves in clinic with a&#xD;
             distal radius fracture due to a trauma.&#xD;
&#xD;
          -  Patients with a stable distal radius fracture treated by cast immobilization.&#xD;
&#xD;
          -  Patients who understand the conditions of the study and are willing and able to comply&#xD;
             with the scheduled biochemical and radiographic evaluations and the prescribed&#xD;
             rehabilitation.&#xD;
&#xD;
          -  Patients who signed the Ethics Committee approved specific Informed Consent Form prior&#xD;
             to inclusion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who underwent surgery of the wrist or radius on a previous occasion on the&#xD;
             same side or who need surgery this time.&#xD;
&#xD;
          -  Patients with active or suspected infection such as pneumonia or complicated urinary&#xD;
             tract infection in the last 3 months.&#xD;
&#xD;
          -  Patients with malignancy or a pathological fracture in the last 12 months.&#xD;
&#xD;
          -  Patients with a neuromuscular or neurosensory deficit, e.g. Parkinson's disease, which&#xD;
             would limit the ability to assess the performance during the healing period.&#xD;
&#xD;
          -  Patients with known systemic or metabolic disorders leading to progressive bone&#xD;
             deterioration, such as: hyperthyroidism, hyperparathyroidism, chronic kidney disease&#xD;
             with eGFR&lt;30 ml/min, sarcoidosis, hypercalcemia,&#xD;
&#xD;
          -  Patients with an active inflammatory disease during the last year such as rheumatoid&#xD;
             arthritis, systemic lupus erythematous, inflammatory bowel disease, e.g. Crohn's&#xD;
             disease and ulcerative colitis.&#xD;
&#xD;
          -  The use of glucocorticoids during the last 12 months.&#xD;
&#xD;
          -  Patients with an allergy to calcium, calcium carbonate, cholecalciferol, aspartame,&#xD;
             citric-acid, lactose, dimethicone, methylcellulose, sorbic acid, macrogole,&#xD;
             polyvidone, mannitol, orange flavour, natriumsaccharine, starch or sucrose.&#xD;
&#xD;
          -  Patients, who as judged by the principal Investigator, are mentally incompetent or are&#xD;
             unlikely to be compliant with the follow-up evaluation schedule.&#xD;
&#xD;
          -  Patients with other severe concurrent joint involvements that can affect their&#xD;
             outcome.&#xD;
&#xD;
          -  Patients who are already selected for another trial concerning distal radius&#xD;
             fractures.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J PW van den Bergh, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VieCuri Medical Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>C E Wyers, PhD</last_name>
    <phone>+31773205555</phone>
    <email>cwyers@viecuri.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>F Heyer, MD</last_name>
    <phone>+31773205555</phone>
    <email>f.heyer@maastrichtuniversity.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>VieCuri Medical Centre</name>
      <address>
        <city>Venlo</city>
        <state>Limburg</state>
        <zip>5912BL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>F Heyer, MD</last_name>
      <phone>+31773205555</phone>
      <email>f.heyer@maastrichtuniversity.nl</email>
    </contact>
    <contact_backup>
      <last_name>C E Wyers, PhD</last_name>
      <phone>+31773205555</phone>
      <email>cwyers@viecuri.nl</email>
    </contact_backup>
    <investigator>
      <last_name>J PW van den Bergh, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>September 26, 2014</study_first_submitted>
  <study_first_submitted_qc>August 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2016</study_first_posted>
  <last_update_submitted>June 8, 2018</last_update_submitted>
  <last_update_submitted_qc>June 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VieCuri Medical Centre</investigator_affiliation>
    <investigator_full_name>Joop P.W. van den Bergh</investigator_full_name>
    <investigator_title>Prof. dr. J.P.W. van den Bergh, Endocrinologist</investigator_title>
  </responsible_party>
  <keyword>Fracture healing</keyword>
  <keyword>Calcium supplementation</keyword>
  <keyword>Vitamin D supplementation</keyword>
  <keyword>HR-pQCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

